動(dòng)物細(xì)胞工程制藥的研究進(jìn)展-資料下載頁(yè)
2025-09-24 17:07本頁(yè)面
【正文】 乃蕊,2006,15(2)：209213.[9]張京航，賀武. ,13(2):25.[10]Avigan D, Vasir B, Gong J, et Cell Vaccination of Patientswith Metastatic Breast and Renal CancerInduces Immunological and Cancer Res[J].2004,10(14):46994708.[11]康玉, / 樹突狀細(xì)胞融合疫苗的臨床應(yīng)用. 國(guó)際免疫學(xué)雜志 2006,29(4):225229.[12][13]沈子龍,[J]. 中國(guó)藥科大學(xué)學(xué)報(bào),2002,33(2)8186.[14]Brink MF, Bishop MD, Pieper efficient strategies for thegeneration of transgenic cattle whichproduce biopharmaceuticals in milk[J].,53(1):139142[15]Zakhartchenko V,Sehernthaner W,Prelle K,et a1．Nuclear transfer inthe bovine embryo: developmental potential of cultured adult cells[J]．, 51: 218．[16]邱志芳,章孝榮,. 生物技術(shù)通訊,2005,16(2):213221.[17]郭黠,謝輝,l2(5):268270.[18]Schnieke AS,Kind AJ,Ritchie WA,et a1．Human factor 9 transgenic sheepproduced by transfer of nuclei，fromtransfectedfetalfibroblasts[J].Science,1997,278:2130 2133.[19] Cibeli JB,Stice S L,Golueke P,et a1．Cloned transgenic calvesproduced fromnonquiscent fetal fibroblasts[J]．Science,1998,280：12561258．[20]王佃亮, . 中國(guó)生物工程雜志. 2003,23(11):2427.[21]Hui Zhu,ShangTian continuous production of monoclonal antibody by hybridoma cellsimmobilized in a fibrousbedbioreactor[J]. Cytotechnology 2004,44:114.[22]米力，. ,23(7):16.內(nèi)容總結(jié)
（1）動(dòng)物細(xì)胞工程制藥的研究進(jìn)展
1161001413167 劉星星
摘 要：動(dòng)物細(xì)胞工程制藥是動(dòng)物細(xì)胞技術(shù)在生物制藥工業(yè)方面的應(yīng)用
（2）二倍體細(xì)胞系一般從動(dòng)物胚胎組織中獲取，有明顯的貼壁和接觸抑制特性，有正常細(xì)胞的核型，一般可傳代培養(yǎng) 5 0 代，且無致瘤性，現(xiàn)在C C L 已被廣泛用于人用治療性藥物的生產(chǎn)，但仍不是理想的生產(chǎn)細(xì)胞系
第 12 頁(yè) 共 12 頁(yè)
黨政相關(guān)相關(guān)推薦
鄂ICP備17016276號(hào)-1